Market capitalization | DKK49.10b |
Enterprise Value | DKK41.27b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 658.28 |
P/S ratio (TTM) P/S ratio | 783.25 |
P/B ratio (TTM) P/B ratio | 5.70 |
Revenue growth (TTM) Revenue growth | -81.71% |
Revenue (TTM) Revenue | DKK62.69m |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
13 Analysts have issued a Zealand Pharma forecast:
13 Analysts have issued a Zealand Pharma forecast:
Dec '24 |
+/-
%
|
||
Revenue | 63 63 |
82%
82%
|
|
Gross Profit | 29 29 |
-
|
|
EBITDA | -1,243 -1,243 |
-
|
EBIT (Operating Income) EBIT | -1,269 -1,269 |
126%
126%
|
Net Profit | -1,079 -1,079 |
53%
53%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
Head office | Denmark |
CEO | Adam Steensberg |
Employees | 335 |
Founded | 1997 |
Website | www.zealandpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.